US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
John Leite, the Chief Commercial Officer-CLIA at Veracyte, Inc. (NASDAQ:VCYT), a $2.37 billion market cap company with strong financial health according to InvestingPro, recently executed a series of stock transactions, according to a recent SEC filing. On March 6, 2025, Leite acquired 36,240 shares of Veracyte common stock through restricted stock units, which are set to vest over a period starting in 2026.
On the following day, March 7, 2025, Leite sold a total of 7,411 shares in two separate transactions. The sales, executed under a pre-established Rule 10b5-1 trading plan, fetched a total of $234,629, with shares sold at prices ranging from $31.035 to $31.9588. After these transactions, Leite’s direct ownership in Veracyte stands at 100,249 shares.
These transactions reflect routine financial planning activities by company executives and are part of Leite’s ongoing management of his equity holdings in Veracyte. For deeper insights into insider trading patterns and 12+ additional ProTips about Veracyte’s financial health, visit InvestingPro.
In other recent news, Veracyte, Inc. reported a strong financial performance for the fourth quarter of 2024, with earnings per share (EPS) of $0.36, significantly surpassing the forecasted $0.10. The company’s revenue for the quarter reached $118.6 million, exceeding expectations by $1.92 million. Despite this earnings beat, Veracyte’s stock experienced a decline, which analysts attribute to strategic uncertainties and potential restructuring costs in France. The company has not provided full 2025 revenue guidance due to ongoing evaluations of its French subsidiary’s ownership, although it projects testing revenue between $470 million and $480 million, indicating 12-15% growth. Needham has maintained a Buy rating on Veracyte, with a price target of $51.00, highlighting confidence in the company’s business fundamentals despite challenges. Veracyte’s DECIPHER and Afirma tests have shown robust growth, contributing significantly to the company’s revenue, with DECIPHER test volumes growing 36% year-over-year. The company’s adjusted EBITDA margin improved by 690 basis points year-over-year, reflecting a strong operational performance. Veracyte’s management remains optimistic about its growth trajectory, focusing on launching new tests and expanding its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.